Slingshot Insights | Exel Overview

EXEL Overview

Upcoming Projects (EXEL)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (EXEL)

Discussing the recent results from the Phase 3 CONTACT-02 clinical Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Tickers: RHHBY, EXEL, IPSEY
Executed On: Sep 22, 2023 at 02:00 PM EDT
A Third Look: Renal cell carcinoma (RCC), with focus on the recent ESMO presentation on the Phase 3 COSMIC-313 trial data from Exelixis. A trial evaluating the Cabometyx+Opdivo+Yervoy) triplet as 1st line for patients previously untreated
Ticker: EXEL
Executed On: Oct 03, 2022 at 12:00 PM EDT
A second Look: Renal cell carcinoma (RCC), with focus on the recent ESMO presentation on the Phase 3 COSMIC-313 trial data from Exelixis. A trial evaluating the Cabometyx+Opdivo+Yervoy) triplet as 1st line for patients previously untreated
Ticker: EXEL
Executed On: Sep 28, 2022 at 04:00 PM EDT
Renal cell carcinoma (RCC), with focus on the recent ESMO presentation on the Phase 3 COSMIC-313 trial data from Exelixis. A trial evaluating the Cabometyx+Opdivo+Yervoy) triplet as 1st line for patients previously untreated advanced kidney
Ticker: EXEL
Executed On: Sep 20, 2022 at 02:30 PM EDT

Upcoming & Overdue Catalysts (EXEL)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (EXEL)

Don’t see a strategic initiative related to the company you care about? Create your own!